Publication: Enhancement of red blood cell transfusion compatibility using CRISPR-mediated erythroblast gene editing
Issued Date
2018-06-01
Resource Type
ISSN
17574684
17574676
17574676
Other identifier(s)
2-s2.0-85045932738
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
EMBO Molecular Medicine. Vol.10, No.6 (2018)
Suggested Citation
Joseph Hawksworth, Timothy J. Satchwell, Marjolein Meinders, Deborah E. Daniels, Fiona Regan, Nicole M. Thornton, Marieangela C. Wilson, Johannes G.G. Dobbe, Geert J. Streekstra, Kongtana Trakarnsanga, Kate J. Heesom, David J. Anstee, Jan Frayne, Ashley M. Toye Enhancement of red blood cell transfusion compatibility using CRISPR-mediated erythroblast gene editing. EMBO Molecular Medicine. Vol.10, No.6 (2018). doi:10.15252/emmm.201708454 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/45158
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Enhancement of red blood cell transfusion compatibility using CRISPR-mediated erythroblast gene editing
Abstract
© 2018 The Authors. Published under the terms of the CC BY 4.0 license Regular blood transfusion is the cornerstone of care for patients with red blood cell (RBC) disorders such as thalassaemia or sickle-cell disease. With repeated transfusion, alloimmunisation often occurs due to incompatibility at the level of minor blood group antigens. We use CRISPR-mediated genome editing of an immortalised human erythroblast cell line (BEL-A) to generate multiple enucleation competent cell lines deficient in individual blood groups. Edits are combined to generate a single cell line deficient in multiple antigens responsible for the most common transfusion incompatibilities: ABO (Bombay phenotype), Rh (Rh null ), Kell (K 0 ), Duffy (Fy null ), GPB (S−s−U−). These cells can be differentiated to generate deformable reticulocytes, illustrating the capacity for coexistence of multiple rare blood group antigen null phenotypes. This study provides the first proof-of-principle demonstration of combinatorial CRISPR-mediated blood group gene editing to generate customisable or multi-compatible RBCs for diagnostic reagents or recipients with complicated matching requirements.